最新ACC/ESC血小板糖蛋白Ⅱb/Ⅲa抑制剂相关指南解读

[1] Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial..Holger Thiele;Jochen Whrle;Rainer Hambrecht;Harald Rittger;Ralf Birkemeyer;Bernward Lauer;Petra Neuhaus;Gerhard Schuler;.The Lancet.2012,

[2] 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.[J].Hani Jneid;Jeffrey L. Anderson;R. Scott Wright;Cynthia D. Adams;Charles R. Bridges;Donald E. Casey;Steven M. Ettinger;Francis M. Fesmire;Theodore G. Ganiats;A. Michael Lin

[3] Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: A meta-analysis of 8 randomized trials [J]. ATHEROSCLEROSIS, 2012, 222 (02) : 426 - 433

[4] 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions [J]. CIRCULATION, 2011, 124 (23) : 2574 - 2609

[5] Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (10) : 917 - 924

[6] Abbreviated Infusion of Eptifibatide After Successful Coronary Intervention.[J].Anthony Y. Fung;Jacqueline Saw;Andrew Starovoytov;Cameron Densem;Percy Jokhi;Simon J. Walsh;Rebecca S. Fox;Karin H. Humphries;Eve Aymong;Donald R. Ricci;John G. Webb;Jaap N. Hamburger;Ronald G. Carere;Christopher E. Buller.Journal of the American College of Cardiology.2009, 10

[7] Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study [J]. CIRCULATION, 2009, 119 (25) : 3215 - 3222

[8] Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel Nonresponders.[J].Thomas Cuisset;Corinne Frere;Jacques Quilici;Pierre-Emmanuel Morange;Jean-Philippe Mouret;Laurent Bali;Pierre-Julien Moro;Marc Lambert;Marie-Christine Alessi;Jean Louis Bonnet.JACC: Cardiovascular Interventions.2008, 6

[9] Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel [J]. CIRCULATION, 2004, 110 (24) : 3627 - 3635

[1] Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial..Holger Thiele;Jochen Whrle;Rainer Hambrecht;Harald Rittger;Ralf Birkemeyer;Bernward Lauer;Petra Neuhaus;Gerhard Schuler;.The Lancet.2012,

[2] 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.[J].Hani Jneid;Jeffrey L. Anderson;R. Scott Wright;Cynthia D. Adams;Charles R. Bridges;Donald E. Casey;Steven M. Ettinger;Francis M. Fesmire;Theodore G. Ganiats;A. Michael Lin

[3] Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: A meta-analysis of 8 randomized trials [J]. ATHEROSCLEROSIS, 2012, 222 (02) : 426 - 433

[4] 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions [J]. CIRCULATION, 2011, 124 (23) : 2574 - 2609

[5] Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (10) : 917 - 924

[6] Abbreviated Infusion of Eptifibatide After Successful Coronary Intervention.[J].Anthony Y. Fung;Jacqueline Saw;Andrew Starovoytov;Cameron Densem;Percy Jokhi;Simon J. Walsh;Rebecca S. Fox;Karin H. Humphries;Eve Aymong;Donald R. Ricci;John G. Webb;Jaap N. Hamburger;Ronald G. Carere;Christopher E. Buller.Journal of the American College of Cardiology.2009, 10

[7] Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study [J]. CIRCULATION, 2009, 119 (25) : 3215 - 3222

[8] Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel Nonresponders.[J].Thomas Cuisset;Corinne Frere;Jacques Quilici;Pierre-Emmanuel Morange;Jean-Philippe Mouret;Laurent Bali;Pierre-Julien Moro;Marc Lambert;Marie-Christine Alessi;Jean Louis Bonnet.JACC: Cardiovascular Interventions.2008, 6

[9] Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel [J]. CIRCULATION, 2004, 110 (24) : 3627 - 3635